Lisocabtagen Maraleucel - Breyanzi® (USA)
According to the NCI website lisocabtagene maraleucel is a preparation of a defined ratio of CD4+ and CD8+ autologous T lymphocytes transduced with a lentiviral vector. Check for active clinical trials using this agent. (NCI Thesaurus)
Link to National Cancer Institute